A prevalence of 4% PPM1D gene mutations was previously reported in a targeted sequencing study on the stem cell products of myeloma patients treated by ASCT at the Dana-Farber Cancer Institute [17]. The gene discussed is PPM1D; the disease is plasma cell myeloma.